PE20161096A1 - INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) - Google Patents
INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)Info
- Publication number
- PE20161096A1 PE20161096A1 PE2016001267A PE2016001267A PE20161096A1 PE 20161096 A1 PE20161096 A1 PE 20161096A1 PE 2016001267 A PE2016001267 A PE 2016001267A PE 2016001267 A PE2016001267 A PE 2016001267A PE 20161096 A1 PE20161096 A1 PE 20161096A1
- Authority
- PE
- Peru
- Prior art keywords
- tgfß
- protein
- growth factor
- fragment
- binding
- Prior art date
Links
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title abstract 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title abstract 5
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 102000003839 Human Proteins Human genes 0.000 abstract 2
- 108090000144 Human Proteins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 abstract 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 abstract 1
- 102000049939 Smad3 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
Abstract
Se refiere a: i) una proteina caracterizada porque comprende: a) un TGFßRII o un fragmento del mismo capaz de unirse a TGFß y b) un anticuerpo, o un fragmento de union a antigeno del mismo, que se une a la proteina humana Ligando 1 de muerte programada (PD-L1); y ii) un polipeptido caracterizado porque comprende: a) al menos un dominio variable de una cadena pesada de un anticuerpo que se une a la proteina humana PD-L1 y b) TGFßRII o un fragmento del mismo capaz de unirse a TGFß. Tambien se refiere a un metodo de produccion de dicha proteina y a un metodo de tratamiento. Dicha proteina inhibe la fosforilacion de SMAD3 en una celula o promueve el agotamiento local de TGFß en un tumor, siendo util en el tratamiento de cancer o en la inhibicion del crecimiento tumoral
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938048P | 2014-02-10 | 2014-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161096A1 true PE20161096A1 (es) | 2016-10-22 |
Family
ID=52988007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001267A PE20161096A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
| PE2020002093A PE20210168A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002093A PE20210168A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9676863B2 (es) |
| EP (2) | EP3889172B1 (es) |
| JP (2) | JP6731346B2 (es) |
| KR (1) | KR102363008B1 (es) |
| CN (2) | CN106103488B (es) |
| AU (3) | AU2015213988B2 (es) |
| BR (1) | BR112016014952A2 (es) |
| CL (1) | CL2016002017A1 (es) |
| CY (1) | CY1124408T1 (es) |
| DK (2) | DK3105246T3 (es) |
| ES (2) | ES2876430T3 (es) |
| HR (1) | HRP20210977T1 (es) |
| HU (1) | HUE054873T2 (es) |
| IL (2) | IL246968B (es) |
| LT (1) | LT3105246T (es) |
| MX (2) | MX381141B (es) |
| NZ (1) | NZ721364A (es) |
| PE (2) | PE20161096A1 (es) |
| PH (1) | PH12016501549A1 (es) |
| PL (1) | PL3105246T3 (es) |
| PT (1) | PT3105246T (es) |
| RS (1) | RS62038B1 (es) |
| RU (2) | RU2021114500A (es) |
| SG (2) | SG11201606577YA (es) |
| SI (1) | SI3105246T1 (es) |
| SM (1) | SMT202100542T1 (es) |
| WO (1) | WO2015118175A2 (es) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3036262A4 (en) | 2013-08-22 | 2017-03-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii variants and uses thereof |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| HUE054873T2 (hu) | 2014-02-10 | 2021-10-28 | Merck Patent Gmbh | Célzott TGF-béta-gátlás |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| JP6877339B2 (ja) | 2014-10-14 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−ｌ１に対する抗体分子およびその使用 |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| JP6901400B2 (ja) * | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| ES3028883T3 (en) | 2015-08-31 | 2025-06-20 | Nat Res Council Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| EP3352800B1 (en) * | 2015-09-24 | 2022-01-05 | The University of North Carolina at Chapel Hill | Methods and compositions for reducing metastases |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| EP3458608B1 (en) * | 2016-05-17 | 2025-07-23 | F. Hoffmann-La Roche AG | Stromal gene signatures for diagnosis and use in immunotherapy |
| CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| WO2018029367A1 (en) * | 2016-08-12 | 2018-02-15 | Merck Patent Gmbh | Combination therapy for cancer |
| KR102617453B1 (ko) | 2016-09-19 | 2023-12-26 | 현대모비스 주식회사 | 보조 표지판 인식 장치 및 그 방법 |
| US10906957B2 (en) | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
| AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| KR20190102059A (ko) * | 2017-01-07 | 2019-09-02 | 메르크 파텐트 게엠베하 | 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태 |
| CN118406655A (zh) * | 2017-01-10 | 2024-07-30 | 普瑞赛格恩公司 | 通过新基因开关表达系统调节多肽的表达 |
| GB201700567D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| KR20190103226A (ko) | 2017-01-13 | 2019-09-04 | 아게누스 인코포레이티드 | Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법 |
| US11866481B2 (en) | 2017-03-02 | 2024-01-09 | National Research Council Of Canada | TGF-β-receptor ectodomain fusion molecules and uses thereof |
| EP3600410A1 (en) * | 2017-03-30 | 2020-02-05 | Merck Patent GmbH | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2018204363A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
| EP4241848A3 (en) * | 2017-05-04 | 2023-11-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| CA3063087A1 (en) * | 2017-05-09 | 2018-11-15 | Julius Y. STRAUSS | Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies |
| JP7264827B2 (ja) * | 2017-05-12 | 2023-04-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途 |
| US20210246227A1 (en) | 2017-05-31 | 2021-08-12 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF |
| WO2019067770A1 (en) | 2017-09-27 | 2019-04-04 | Epicentrx, Inc. | IMMUNOMODULATORY FUSION PROTEINS |
| ES2984919T3 (es) * | 2017-11-06 | 2024-10-31 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| WO2019113464A1 (en) * | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| AR114275A1 (es) | 2018-03-09 | 2020-08-12 | Agenus Inc | Anticuerpos anti-cd73 y métodos de uso de los mismos |
| MX2020009478A (es) | 2018-03-14 | 2020-10-22 | Merck Patent Gmbh | Compuestos y sus usos para tratar tumores en un paciente. |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20210005646A (ko) | 2018-04-26 | 2021-01-14 | 아게누스 인코포레이티드 | 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법 |
| WO2019213442A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
| JP2021522795A (ja) * | 2018-05-03 | 2021-09-02 | アクセルロン ファーマ インコーポレイテッド | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |
| KR20210006405A (ko) | 2018-05-04 | 2021-01-18 | 메르크 파텐트 게엠베하 | 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제 |
| CN112118858A (zh) * | 2018-05-15 | 2020-12-22 | 默克专利有限公司 | 用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案 |
| CN112153988A (zh) | 2018-05-17 | 2020-12-29 | 博尔特生物治疗药物有限公司 | 免疫缀合物 |
| WO2019241353A1 (en) * | 2018-06-13 | 2019-12-19 | Merck Patent Gmbh | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
| US11912763B2 (en) | 2018-06-17 | 2024-02-27 | L & L Biopharma Co., Ltd. | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof |
| TW202019959A (zh) * | 2018-06-22 | 2020-06-01 | 德商馬克專利公司 | 用於治療膽道癌的標靶性tgf-b抑制之給藥方案 |
| JP2021529556A (ja) | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． | 抗腫瘍アンタゴニスト |
| BR112020026902A2 (pt) * | 2018-07-02 | 2021-03-30 | Merck Patent Gmbh | Terapia combinada com inibição direcionada de tgf-b para o tratamento de câncer de pulmão de células não pequenas avançado |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN120775065A (zh) * | 2018-07-09 | 2025-10-14 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| KR20210046716A (ko) * | 2018-08-22 | 2021-04-28 | 메르크 파텐트 게엠베하 | 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료 |
| EP3856350A1 (en) | 2018-09-27 | 2021-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| AU2019371457A1 (en) | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Anti-TIM-3 antibodies |
| CA3117371A1 (en) | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Methods of administering anti-tim-3 antibodies |
| BR112021008288A2 (pt) | 2018-11-09 | 2021-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma |
| WO2020118094A1 (en) * | 2018-12-06 | 2020-06-11 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| WO2020190734A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting pd-l1 |
| CN114206926B (zh) | 2019-06-10 | 2022-06-17 | 山东博安生物技术股份有限公司 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
| US20200390899A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| CN110218260A (zh) * | 2019-06-24 | 2019-09-10 | 王跃驹 | 植物作为宿主在表达m7842中的应用 |
| CN114340735B (zh) * | 2019-06-28 | 2024-11-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| EP4013507A1 (en) * | 2019-08-15 | 2022-06-22 | NantBio, Inc. | Tgf-beta trap |
| MX2022002315A (es) | 2019-08-30 | 2022-03-25 | Agenus Inc | Anticuerpos anti-cd96 y sus metodos de uso. |
| WO2021037184A1 (zh) | 2019-08-30 | 2021-03-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
| CN114630684A (zh) | 2019-09-03 | 2022-06-14 | 博尔特生物治疗药物有限公司 | 氨基喹啉化合物、免疫缀合物及其用途 |
| US20220347312A1 (en) | 2019-09-04 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Immunoconjugate Synthesis Method |
| CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
| CN115947846A (zh) | 2019-09-12 | 2023-04-11 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| EP4038053A1 (en) | 2019-09-30 | 2022-08-10 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| TWI832013B (zh) * | 2019-09-30 | 2024-02-11 | 大陸商諾納生物（蘇州）有限公司 | 一種抗pd-l1抗原結合蛋白及其應用 |
| JP7495489B2 (ja) * | 2019-10-21 | 2024-06-04 | ナンチン リーズ バイオラブス カンパニー，リミティド | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
| CA3154413A1 (en) * | 2019-11-01 | 2021-05-06 | Yan Lan | Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer |
| AU2020379201A1 (en) * | 2019-11-05 | 2022-05-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer |
| WO2021093760A1 (zh) * | 2019-11-12 | 2021-05-20 | 江苏恒瑞医药股份有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| CN114746451A (zh) * | 2019-11-27 | 2022-07-12 | 上海岸迈生物科技有限公司 | TGFβ/PD-L1双特异性结合蛋白 |
| WO2021115456A1 (en) * | 2019-12-11 | 2021-06-17 | Wuxi Biologics (Shanghai) Co., Ltd. | BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ |
| US20230043290A1 (en) * | 2019-12-20 | 2023-02-09 | Ares Trading S.A. | Igg:tgfbetarii fusion protein composition |
| EP3838260A1 (en) | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
| CN113004414B (zh) * | 2019-12-20 | 2022-09-06 | 广东菲鹏制药股份有限公司 | 抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物 |
| CN113121699A (zh) * | 2019-12-30 | 2021-07-16 | 国典(北京)医药科技有限公司 | Pttrap1双特异性融合蛋白及其应用 |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN114929734A (zh) * | 2020-01-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 新型含有4-1bbl三聚体的抗原结合分子 |
| WO2021150702A1 (en) | 2020-01-21 | 2021-07-29 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 antibodies |
| CN115151308A (zh) | 2020-01-21 | 2022-10-04 | 博尔特生物治疗药物有限公司 | 抗pd-l1抗体 |
| CN115135675A (zh) * | 2020-02-18 | 2022-09-30 | 南京金斯瑞生物科技有限公司 | 融合蛋白及其用途 |
| TWI813951B (zh) * | 2020-02-25 | 2023-09-01 | 大陸商上海藥明生物技術有限公司 | 一種雙功能融合蛋白及其用途 |
| JP7489468B2 (ja) * | 2020-03-20 | 2024-05-23 | レメゲン シーオー．，エルティーディー． | 二重特異性融合タンパク質及びその応用 |
| JP2023521465A (ja) | 2020-04-14 | 2023-05-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療 |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
| CA3181579A1 (en) * | 2020-04-29 | 2021-11-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bifunctional protein against pd-1 and tgf-.beta. |
| CR20220582A (es) | 2020-05-01 | 2023-01-09 | Bolt Biotherapeutics Inc | Anticuerpos anti-dectina-2 |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| JP2023532279A (ja) * | 2020-06-26 | 2023-07-27 | ソレント・セラピューティクス・インコーポレイテッド | 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ） |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| EP4194002A4 (en) * | 2020-07-24 | 2024-08-14 | Mabwell (Shanghai) Bioscience Co., Ltd. | TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN |
| US11028174B1 (en) | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| CN121319180A (zh) * | 2020-07-28 | 2026-01-13 | 乐普生物科技股份有限公司 | 靶向PD-L1和TGF-β的双功能分子 |
| WO2022042537A1 (zh) * | 2020-08-24 | 2022-03-03 | 江苏恒瑞医药股份有限公司 | TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途 |
| CN116249718A (zh) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | 结合至钙网蛋白的多功能性分子及其用途 |
| WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
| CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN114106190B (zh) | 2020-08-31 | 2025-04-08 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| CN115884989A (zh) * | 2020-08-31 | 2023-03-31 | 杭州九源基因工程有限公司 | 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用 |
| WO2022057061A1 (en) * | 2020-09-16 | 2022-03-24 | Suzhou Neologics Bioscience Co., Ltd. | Pd-l1 antibodies, fusion proteins, and uses thereof |
| EP4165086A4 (en) * | 2020-09-16 | 2024-07-31 | Suzhou Neologics Bioscience Co., Ltd. | Pd-l1 antibodies, fusion proteins, and uses thereof |
| CN116390940A (zh) * | 2020-09-23 | 2023-07-04 | 海正生物制药有限公司 | Tgfbr2-ecd突变体及包含其的融合蛋白与应用 |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| CN114349867B (zh) * | 2020-10-14 | 2024-05-28 | 广东菲鹏制药股份有限公司 | 融合蛋白及其应用 |
| CA3196557A1 (en) | 2020-11-02 | 2022-05-05 | Ada SALA-HOJMAN | Combination treatment of cancer |
| CA3196550A1 (en) | 2020-11-02 | 2022-05-05 | Yan Lan | Combination treatment of cancer |
| CN114573701A (zh) * | 2020-12-02 | 2022-06-03 | 上海华奥泰生物药业股份有限公司 | 抗PD-L1/TGF-β双功能抗体及其用途 |
| JP2024501453A (ja) | 2020-12-11 | 2024-01-12 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｃｅａイムノコンジュゲート、及びそれらの使用 |
| US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| CN116723866A (zh) | 2020-12-11 | 2023-09-08 | 博尔特生物治疗药物有限公司 | 抗pd-l1免疫缀合物和其用途 |
| WO2022174451A1 (zh) | 2021-02-22 | 2022-08-25 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| EP4301733A1 (en) | 2021-03-02 | 2024-01-10 | GlaxoSmithKline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| JP2024511088A (ja) | 2021-03-26 | 2024-03-12 | ボルト バイオセラピューティクス、インコーポレーテッド | ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用 |
| CA3212907A1 (en) | 2021-03-26 | 2022-09-29 | Gary Brandt | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
| CN114773485B (zh) * | 2021-05-11 | 2024-05-17 | 江苏先声药业有限公司 | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 |
| CN117999101A (zh) | 2021-05-25 | 2024-05-07 | 默克专利股份公司 | 靶向EGFR的Fc抗原结合片段-药物缀合物 |
| US20240279338A1 (en) | 2021-06-07 | 2024-08-22 | Ares Trading S.A. | Combination Treatment of Cancer |
| JP2024534263A (ja) * | 2021-08-27 | 2024-09-18 | セラノティックス カンパニー リミテッド | Ｂ７－Ｈ３及びＴＧＦβに特異的に結合する二重特異性分子、並びにその用途 |
| JP2025504945A (ja) | 2022-01-28 | 2025-02-19 | ３５ファーマ インコーポレイテッド | アクチビン受容体ｉｉｂ型バリアント及びその使用 |
| CN114990129B (zh) * | 2022-05-11 | 2023-02-03 | 北京贝来生物科技有限公司 | 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用 |
| TWI866210B (zh) | 2022-05-17 | 2024-12-11 | 大陸商蘇州創勝醫藥集團有限公司 | 雙功能蛋白質及其製劑和用途 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| WO2024216089A1 (en) | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
| US20250136663A1 (en) * | 2023-10-31 | 2025-05-01 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| KR20250078792A (ko) * | 2023-11-24 | 2025-06-04 | 주식회사 메드팩토 | 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도 |
| WO2025140212A1 (en) * | 2023-12-26 | 2025-07-03 | Laekna Therapeutics Shanghai Co., Ltd. | Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof |
| EP4653010A1 (en) | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| DK0975771T3 (da) * | 1997-04-18 | 2007-10-22 | Biogen Idec Inc | Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region |
| DE60122286T2 (de) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| JP2005112812A (ja) * | 2003-10-09 | 2005-04-28 | Zeria Pharmaceut Co Ltd | リン酸化部位特異的抗体及びそれを用いたスクリーニング方法 |
| CN1921864A (zh) * | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF－β抑制剂治疗神经胶质瘤 |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| EP2171062A1 (en) | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| US20140127200A1 (en) | 2008-01-03 | 2014-05-08 | The Scripps Research Institute | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| AU2009266873A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | TGF-beta antagonist multi-target binding proteins |
| EP4331604B9 (en) * | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| FR2944448B1 (fr) * | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| WO2011059762A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| US20130129723A1 (en) * | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| HUE029257T2 (en) * | 2009-12-29 | 2017-02-28 | Aptevo Res And Dev Llc | Heterodimer binding proteins and their use |
| RU2012140447A (ru) | 2010-02-23 | 2014-03-27 | Дженентек, Инк. | Антиангиогенная терапия для лечения рака яичника |
| PL2542590T5 (pl) | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
| KR20190133790A (ko) * | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| CA2947354C (en) * | 2012-04-30 | 2024-03-19 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| MX363872B (es) | 2012-05-31 | 2019-04-05 | Genentech Inc | Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cáncer. |
| ES2822665T3 (es) | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| HUE054873T2 (hu) | 2014-02-10 | 2021-10-28 | Merck Patent Gmbh | Célzott TGF-béta-gátlás |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| LT3180363T (lt) | 2014-08-15 | 2019-11-25 | Merck Patent Gmbh | Sirp-alfa imunoglobulino sulieti baltymai |
-
2015
- 2015-02-10 HU HUE15717097A patent/HUE054873T2/hu unknown
- 2015-02-10 SI SI201531639T patent/SI3105246T1/sl unknown
- 2015-02-10 JP JP2016546949A patent/JP6731346B2/ja active Active
- 2015-02-10 NZ NZ721364A patent/NZ721364A/en unknown
- 2015-02-10 HR HRP20210977TT patent/HRP20210977T1/hr unknown
- 2015-02-10 CN CN201580007865.3A patent/CN106103488B/zh active Active
- 2015-02-10 MX MX2016010067A patent/MX381141B/es unknown
- 2015-02-10 PL PL15717097T patent/PL3105246T3/pl unknown
- 2015-02-10 WO PCT/EP2015/052781 patent/WO2015118175A2/en not_active Ceased
- 2015-02-10 RU RU2021114500A patent/RU2021114500A/ru unknown
- 2015-02-10 AU AU2015213988A patent/AU2015213988B2/en active Active
- 2015-02-10 EP EP21165709.3A patent/EP3889172B1/en active Active
- 2015-02-10 DK DK15717097.8T patent/DK3105246T3/da active
- 2015-02-10 ES ES15717097T patent/ES2876430T3/es active Active
- 2015-02-10 LT LTEP15717097.8T patent/LT3105246T/lt unknown
- 2015-02-10 RS RS20210783A patent/RS62038B1/sr unknown
- 2015-02-10 SM SM20210542T patent/SMT202100542T1/it unknown
- 2015-02-10 DK DK21165709.3T patent/DK3889172T3/da active
- 2015-02-10 ES ES21165709T patent/ES2992668T3/es active Active
- 2015-02-10 SG SG11201606577YA patent/SG11201606577YA/en unknown
- 2015-02-10 BR BR112016014952A patent/BR112016014952A2/pt not_active Application Discontinuation
- 2015-02-10 RU RU2016135062A patent/RU2752424C2/ru active
- 2015-02-10 SG SG10202108879SA patent/SG10202108879SA/en unknown
- 2015-02-10 PE PE2016001267A patent/PE20161096A1/es unknown
- 2015-02-10 PE PE2020002093A patent/PE20210168A1/es unknown
- 2015-02-10 CN CN202110830081.8A patent/CN113549159A/zh active Pending
- 2015-02-10 KR KR1020167024679A patent/KR102363008B1/ko active Active
- 2015-02-10 US US14/618,454 patent/US9676863B2/en active Active
- 2015-02-10 PT PT157170978T patent/PT3105246T/pt unknown
- 2015-02-10 EP EP15717097.8A patent/EP3105246B1/en active Active
-
2016
- 2016-07-27 IL IL246968A patent/IL246968B/en active IP Right Grant
- 2016-08-03 MX MX2021003685A patent/MX2021003685A/es unknown
- 2016-08-04 PH PH12016501549A patent/PH12016501549A1/en unknown
- 2016-08-10 CL CL2016002017A patent/CL2016002017A1/es unknown
-
2017
- 2017-06-08 US US15/617,876 patent/US20180002436A1/en not_active Abandoned
-
2019
- 2019-07-25 US US16/522,304 patent/US11370819B2/en active Active
- 2019-10-11 AU AU2019246876A patent/AU2019246876B2/en not_active Ceased
-
2020
- 2020-07-06 JP JP2020116566A patent/JP2020174674A/ja active Pending
-
2021
- 2021-03-16 IL IL281565A patent/IL281565B/en unknown
- 2021-06-23 CY CY20211100564T patent/CY1124408T1/el unknown
-
2022
- 2022-01-20 AU AU2022200365A patent/AU2022200365A1/en not_active Abandoned
- 2022-06-07 US US17/834,458 patent/US20230056881A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161096A1 (es) | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| MX373019B (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4). | |
| MX2024009277A (es) | Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos. | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
| BR112016013896A2 (pt) | métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2 | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| IL276303A (en) | Methods of treating cancer with ANTI-PD-1 antibodies | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| NZ724013A (en) | Antibodies that bind egfr and erbb3 | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| MX2024003627A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| WO2016073647A3 (en) | COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS | |
| MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. |